alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                            18 U.S.C. Section #1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q ("Form 10-Q") of Galaxy
Nutritional Foods, Inc. (the "Company") for the period ended June 30, 2006 as
filed with the Securities and Exchange Commission on the date hereof, I,
Salvatore J. Furnari, Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

      (1) The Form 10-Q fully complies with the requirements of Section 13(a) or
      15(d) of the Securities Exchange Act of 1934; and

      (2) The information contained in the Form 10-Q fairly presents, in all
      material respects, the financial condition and results of operations of
      the Company.


                                        /s/ Salvatore J. Furnari
                                        ----------------------------------------
                                        Salvatore J. Furnari
                                        Chief Financial Officer
                                        August 14, 2006
No. 11-10904.

#### Thomas *v.*Alabama Board of Pardons and Paroles.

Ct. Crim. App. Ala. Certiorari denied.
<TABLE>
<CAPTION>
ALL AMERICAN SEMICONDUCTOR, INC. AND SUBSIDIARIES                                              Exhibit 11.1

STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS (UNAUDITED)

                                                                 Quarters                    Nine Months
PERIODS ENDED SEPTEMBER 30                                2002           2001           2002           2001
-----------------------------------------------------------------------------------------------------------

<S>                                              <C>            <C>            <C>            <C>
BASIC EARNINGS PER SHARE:
-------------------------

Net Income (Loss)............................    $   1,559,000  $    (381,000) $   1,876,000  $ (13,692,000)
                                                 =============  =============  =============  =============

Weighted Average Shares Outstanding..........        3,851,185      3,856,904      3,854,998      3,856,904
                                                 =============  =============  =============  =============

Basic Earnings (Loss) Per Share..............          $   .40        $  (.10)       $   .49        $ (3.55)
                                                       =======        =======        =======        =======

DILUTED EARNINGS PER SHARE:
---------------------------

Net Income (Loss)............................    $   1,559,000  $    (381,000) $   1,876,000  $ (13,692,000)
                                                 =============  =============  =============  =============

Weighted Average and Dilutive Shares:
  Weighted average shares outstanding........        3,851,185      3,856,904      3,854,998      3,856,904
  Dilutive shares............................              160              -            127              -
                                                 -------------  -------------  -------------  -------------
                                                     3,851,345      3,856,904      3,855,125      3,856,904
                                                 =============  =============  =============  =============

Diluted Earnings (Loss) Per Share............          $   .40        $  (.10)       $   .49        $ (3.55)
                                                       =======        =======        =======        =======
</TABLE>
<TABLE> <S> <C>

<ARTICLE>     5
<LEGEND>   THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION
 EXTRACTED FROM THE CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 
 1996 AND THE CONSOLIDATED STATEMENT OF OPERATIONS FOR THE SIX- 
 MONTHS ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY
 BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
<MULTIPLIER>  1,000
       
<S>                                   <C>
<PERIOD-TYPE>                         6-MOS
<FISCAL-YEAR-END>                     JUN-30-1997
<PERIOD-END>                          DEC-31-1996
<CASH>                                    17,156
<SECURITIES>                              27,985
<RECEIVABLES>                              2,093
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                          47,567
<PP&E>                                    17,738
<DEPRECIATION>                            13,628
<TOTAL-ASSETS>                            59,150
<CURRENT-LIABILITIES>                      4,004
<BONDS>                                        7
<COMMON>                                      21
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<OTHER-SE>                                55,118
<TOTAL-LIABILITY-AND-EQUITY>              59,150
<SALES>                                        0
<TOTAL-REVENUES>                               0
<CGS>                                          0
<TOTAL-COSTS>                                  0
<OTHER-EXPENSES>                           8,252
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                            12
<INCOME-PRETAX>                           (8,741)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                       (8,741)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                              (8,741)
<EPS-PRIMARY>                              (0.42)
<EPS-DILUTED>                                  0
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE>         5
<LEGEND>
This schedule contains a summary of financial information extracted from the
Condensed Consolidated Balance Sheet and Condensed Consolidated Statement of
Operations and is qualified in its entirety by reference to such financial
statements.
</LEGEND>
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          AUG-01-1998
<PERIOD-END>                               MAY-02-1998
<CASH>                                          13,278
<SECURITIES>                                   165,906      
<RECEIVABLES>                                   61,902
<ALLOWANCES>                                     1,717
<INVENTORY>                                    516,272
<CURRENT-ASSETS>                               822,515
<PP&E>                                         799,596
<DEPRECIATION>                                 330,489
<TOTAL-ASSETS>                               1,413,299
<CURRENT-LIABILITIES>                          369,754
<BONDS>                                        300,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           499
<OTHER-SE>                                     639,852
<TOTAL-LIABILITY-AND-EQUITY>                 1,413,299
<SALES>                                      1,836,618
<TOTAL-REVENUES>                             1,836,618
<CGS>                                        1,231,597
<TOTAL-COSTS>                                1,669,675
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 2,052
<INTEREST-EXPENSE>                              16,802
<INCOME-PRETAX>                                150,141
<INCOME-TAX>                                    60,056
<INCOME-CONTINUING>                             90,085
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    90,085
<EPS-PRIMARY>                                     1.81
<EPS-DILUTED>                                     1.80
        

</TABLE>
## COME, MY **FRIENDS, ‘TIS NOT T** **OO LA**

**TE TO** **SEEK A**  **NEWER WORLD.** 

# Sustainability Metrics in North Carolina State Government Presentation to NACEPT William G. Ross, Jr. August 2, 2012

# Green Square The Nature Research Center and DENR Headquarters

# Environmental Features
• Energy recovery systems, energy star equipment, low VOC paint, insulated walls, low E windows that reflect heat from the sun.

• Roof top solar panels

• Green roof with rainwater collection system.

• Pursuing LEED Gold status • Recycled materials including wood derived from trees cut down on site

• Natural light complements an extensive LED lighting system

## The Environmental Stewardship Initiative

# ESI – By the Numbers 2010 ESI Members Reported Reductions:

• Air Emissions – 46 To ns • Energy – 598,591 mmBtu • Water Use – 41,895,325 Gallons • Landfill Wa ste Disposal – 10,245 To ns TO TAL Cost Savings: $3,270,504

## ESI Measures Reductions and Savings • 

### Air Emissions • 

### Greenhouse Gas Emissions • 

### Hazardous Wa ste • 

### Landfill Wa ste Disposal • 

### Energy • 

### Water Use • 

### Wa stewater Pollutants • 

### Wa stewater V

olume Reduction • 

### Biomass Recovery • 

### Total Recycled Vo lume • 

### Total Cost Savings

# Clean Smokestacks

## Southeastern **Regional Partnership for**

**Planning and Sustainability** 

# SERPP

AS • Progress Toward Mutual And Multiple Goals On A Project By Project Basis • Example – Longleaf Pine Restoration

# For more information

• NC DENR: portal.ncdenr.gov • Nature Research Center: naturalsciences.org/nature research - center • ESI: portal.ncdenr.org/web/deao/outreach/esi • NC Division of Air Quality: daq.state.nc.us • SERPP AS: serppas.org
/**
* DO NOT EDIT THIS FILE.
* See the following change record for more information,
* https://www.drupal.org/node/2815083
* @preserve
**/
if (!Element.prototype.matches) {
  Element.prototype.matches = Element.prototype.msMatchesSelector || Element.prototype.webkitMatchesSelector;
}
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                         6942370
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                   75352090
<INVESTMENTS-CARRYING>                         4631549
<INVESTMENTS-MARKET>                           4711497
<LOANS>                                      146991710
<ALLOWANCE>                                    1696274
<TOTAL-ASSETS>                               244482508
<DEPOSITS>                                   200780281
<SHORT-TERM>                                   5196916
<LIABILITIES-OTHER>                            4543730
<LONG-TERM>                                   14600000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       4002154
<OTHER-SE>                                    15359427
<TOTAL-LIABILITIES-AND-EQUITY>               244482508
<INTEREST-LOAN>                                9500091
<INTEREST-INVEST>                              3226423
<INTEREST-OTHER>                                107825
<INTEREST-TOTAL>                              12834339
<INTEREST-DEPOSIT>                             5620642
<INTEREST-EXPENSE>                             6408127
<INTEREST-INCOME-NET>                          6426212
<LOAN-LOSSES>                                   450000
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                5898224
<INCOME-PRETAX>                                1991642
<INCOME-PRE-EXTRAORDINARY>                     1991642
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   1310092
<EPS-PRIMARY>                                     1.56
<EPS-DILUTED>                                     1.55
<YIELD-ACTUAL>                                    7.95
<LOANS-NON>                                    1214358
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                619560
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               1512038
<CHARGE-OFFS>                                   291537
<RECOVERIES>                                     25773
<ALLOWANCE-CLOSE>                              1696274
<ALLOWANCE-DOMESTIC>                                 0
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                        1696274
        

</TABLE>
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE

SARBANES-OXLEY
ACT OF 2002

In connection with the quarter report on Form 10-Q of National Housing Trust Limited Partnership (the
Partnership) for the period ending September 30, 2005, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James A. Bowman, Chief Executive Officer of NHT, Inc. the general partner of
the Partnership, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Partnership.
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------



|                     |  |  |  |    |  |                     |  |                                                                                                                                 
|-------------------- |  |  |  | -- |  | ------------------- |  | --------------------------------------------------------------------------------------------------------------------------------
|                     |  |  | 
|Date August 31, 2007 |  |  |  | By |  | /s/ James A. Bowman
|                     |  |  |  |    |  |                     |  | James A. Bowman, President and Chief Executive Officer NHT, Inc., General Partner for National Housing Trust Limited Partnership
# C_2022326EN.01002501.xml

| 29.8.2022 | EN | Official Journal of the European Union | C 326/25 |
| --- | --- | --- | --- |

29.8.2022

EN

Official Journal of the European Union

C 326/25

---

Action brought on 6 July 2022 — Laboratorios Ern v EUIPO — Arrowhead Pharmaceuticals (TRiM)

(Case T-428/22)

(2022/C 326/34)

Language in which the application was lodged: English

Parties

Applicant: Laboratorios Ern, SA (Barcelona, Spain) (represented by: S. Correa Rodríguez, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Arrowhead Pharmaceuticals, Inc. (Pasadena, California, United States)

Details of the proceedings before EUIPO

Proprietor of the trade mark at issue: Other party to the proceedings before the Board of Appeal

Trade mark at issue: International registration designating the European Union in respect of the word mark TRiM — International registration designating the European Union No 1 411 062

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Second Board of Appeal of EUIPO of 12 April 2022 in Case R 1158/2021-2

Form of order sought

The applicant claims that the Court should:

| — | revoke the contested decision and reject the European designation of the international trademark No 1 411 062 TRIM for all goods and services; |
| --- | --- |

—

revoke the contested decision and reject the European designation of the international trademark No 1 411 062 TRIM for all goods and services;

| — | impose the costs to the defendant and, in case Arrowhead Pharmaceuticals, Inc. decides to intervene in the present proceedings, to Arrowhead Pharmaceuticals, Inc. |
| --- | --- |

—

impose the costs to the defendant and, in case Arrowhead Pharmaceuticals, Inc. decides to intervene in the present proceedings, to Arrowhead Pharmaceuticals, Inc.

Plea in law

| — | Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.

---
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       261,200
<OTHER-SE>                                   (261,200)
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0   
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
Order entered December 11 , 2019

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05 - 19 - 01291 - CV IN RE JANECIA WATT, R elat or On Appeal from the 304th Judicial District Court

Dallas Cou nty, Texas Trial Court Cause No. JC - 19 - 00707



### O RDER Before the Court is relator’s October 23, 2019 petition for writ of mandamus
. We request that the real party in interest and respondent file their responses, if any, to the petition for writ of mandamus by December 23, 2019
. /s/ DAVID L. BRIDGES JUSTICE
#### COMMONWEALTH of Pennsylvania, Respondent v. Arlando PICKETT, Petitioner

No. 377 EAL 2017

Supreme Court of Pennsylvania.

January 9, 2018

ORDER

PER CURIAM

AND NOW, this 9th day of January, 2018, the Petition for Allowance of Appeal is DENIED.
No. 11-11020.

#### Gaytan v. Hall et al.

C. A. 7th Cir. Certio-rari denied.
<PAGE>

                                                                EXHIBIT 10.1(b)



ALARIS Medical, Inc. hereby agrees to furnish to the Securities and Exchange 
Commission, upon its request, the schedules and exhibits to the Agreement 
dated May 7, 1998 among ALARIS Medical Systems, Inc. and Caesarea Medical 
Electronics Limited filed as Exhibit 10.1(a) to ALARIS Medical, Inc.'s Form 
10-Q dated August 11, 1998.

                                                ALARIS MEDICAL, INC.
                                                -----------------------------
                                                (REGISTRANT)




Date:   August 11, 1998                     By: /s/ DOUGLAS C. JEFFRIES  
                                                -----------------------------
                                                Douglas C. Jeffries
                                                Vice President and Chief 
                                                  Financial Officer
No. 11-597.

#### Arkansas Game and Fish Commission *v.*United States.

C. A. Fed. Cir. [Certiorari granted, 566 U. S. 920.] Motion of professors of law teaching in the property law and water rights fields for leave to file a brief as *amici curiae*
      *968granted.

Justice Kagan took no part in the consideration or decision of this motion.
# C_2022294EN.01003602.xml

| 1.8.2022 | EN | Official Journal of the European Union | C 294/36 |
| --- | --- | --- | --- |

1.8.2022

EN

Official Journal of the European Union

C 294/36

---

Action brought on 10 June 2022 — adp Merkur v EUIPO — Play’n GO Marks (GAME OF GLADIATORS)

(Case T-350/22)

(2022/C 294/52)

Language in which the application was lodged: English

Parties

Applicant: adp Merkur GmbH (Espelkamp, Germany) (represented by: K. Mandel, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Play’n GO Marks ltd. (Sliema, Malta)

Details of the proceedings before EUIPO

Applicant of the trade mark at issue: Other party to the proceedings before the Board of Appeal

Trade mark at issue: Application for European Union word mark GAME OF GLADIATORS — Application for registration No 18 022 754

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 11 April 2022 in Case R 2289/2020-4

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | order EUIPO to bear the costs of the proceedings. |
| --- | --- |

—

order EUIPO to bear the costs of the proceedings.

Plea in law

Infringement of Article 47(2) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.

---